Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

2.50
Hdl Handle:
http://hdl.handle.net/11287/620905
Title:
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Authors:
Parker, C. C. [et al]; Sheehan, Denise J
Abstract:
Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that the benefit would be greatest in patients with a low metastatic burden. We aimed to compare standard of care for metastatic prostate cancer, with and without radiotherapy.
Citation:
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. 2018 Lancet
Publisher:
Elsevier
Journal:
Lancet
Issue Date:
18-Oct-2018
URI:
http://hdl.handle.net/11287/620905
DOI:
10.1016/S0140-6736(18)32486-3
PubMed ID:
30355464
Additional Links:
https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(18)32486-3
Note:
This article is freely available via Open Access.
Type:
Journal Article
Language:
en
ISSN:
1474-547X
Appears in Collections:
Oncology; 2018 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorParker, C. C. [et al]en
dc.contributor.authorSheehan, Denise Jen
dc.date.accessioned2018-11-08T12:52:52Z-
dc.date.available2018-11-08T12:52:52Z-
dc.date.issued2018-10-18-
dc.identifier.citationRadiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. 2018 Lanceten
dc.identifier.issn1474-547X-
dc.identifier.pmid30355464-
dc.identifier.doi10.1016/S0140-6736(18)32486-3-
dc.identifier.urihttp://hdl.handle.net/11287/620905-
dc.description.abstractBased on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that the benefit would be greatest in patients with a low metastatic burden. We aimed to compare standard of care for metastatic prostate cancer, with and without radiotherapy.en
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urlhttps://linkinghub.elsevier.com/retrieve/pii/S0140-6736(18)32486-3en
dc.rightsArchived with thanks to Lancet (London, England). This is an Open Access article under the CC BY 4.0 license.en
dc.subjectWessex Classification Subject Headings::Oncology. Pathology.en
dc.titleRadiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.en
dc.typeJournal Articleen
dc.identifier.journalLanceten
dc.description.noteThis article is freely available via Open Access.en
dc.type.versionIn press (epub ahead of print)en

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.